Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the duration of treatment in ...

Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of ...

Novartis announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR) ...

Winrevair was approved to treat PAH WHO Group 1 in the United States in March based on data from the STELLAR study.

Novartis’ Kisqali (ribociclib) has been approved by the European Commission (EC) to reduce the risk of disease recurrence in ...

The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...

Novartis announced today that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone ...

(RTTNews) - Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone ...